Immutep (IMMP) Retained Earnings (2011 - 2026)
Immutep's (IMMP) quarterly Retained Earnings came in at -$369.4 million in Q2 2026, down 29.9% on a YoY basis from -$527.0 million in Q2 2025, and down 15.69% quarter-over-quarter from -$319.3 million in Q4 2025.
Analysis
Immutep (IMMP) Retained Earnings (2011 - 2026) Analysis & Trends
Immutep (IMMP) has reported Retained Earnings for 16 consecutive years, with -$369.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Retained Earnings fell 29.9% year-over-year to -$369.4 million; the trailing twelve-month figure through Jun 2026 stood at -$369.4 million (down 29.9% YoY), and the FY2026 full-year result was -$369.4 million, down 29.9% from the prior year.
- Retained Earnings retreated to -$369.4 million in Q2 2026 per IMMP's latest filing, from -$319.3 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$210.7 million in Q4 2022 and bottomed at -$369.4 million in Q2 2026.
- Historically, Retained Earnings has averaged -$264.4 million across 5 years, with a median of -$252.2 million in 2024.
- The sharpest annual moves came in 2022 and 2026: Retained Earnings increased 0.59% in 2022, then fell 29.9% in 2026.
- Over 5 years, Retained Earnings stood at -$210.7 million in 2022, then declined by 11.6% to -$235.1 million in 2023, then fell by 12.66% to -$264.9 million in 2024, then fell by 20.56% to -$319.3 million in 2025, then fell by 15.69% to -$369.4 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$369.4 million, -$319.3 million, and -$284.4 million for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Immutep | 52.57 Mn | 52.57 Mn | - | -369.43 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -369.43 Mn |
| Dec 31, 2025 | -319.33 Mn |
| Jun 30, 2025 | -284.40 Mn |
| Dec 31, 2024 | -264.87 Mn |
| Jun 30, 2024 | -252.17 Mn |
| Dec 31, 2023 | -235.11 Mn |
| Jun 30, 2023 | -227.20 Mn |
| Dec 31, 2022 | -210.68 Mn |
| Jun 30, 2022 | -216.55 Mn |
| Dec 31, 2021 | -211.93 Mn |
| Jun 30, 2021 | -211.49 Mn |
| Dec 31, 2020 | -213.12 Mn |
| Jun 30, 2020 | -180.70 Mn |
| Dec 31, 2019 | -183.22 Mn |
| Jun 30, 2019 | -183.69 Mn |
| Jun 30, 2018 | -185.16 Mn |
| Dec 31, 2017 | -181.62 Mn |
| Jun 30, 2017 | -174.16 Mn |
| Mar 31, 2017 | -173.30 Mn |
| Dec 31, 2016 | -226.53 Mn |